



NEWS RELEASE

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com

For Immediate Release:

Nymox Starts Phase 3 Program for NX-1207

HASBROUCK HEIGHTS, NJ (June 9, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that, following recent communications with the U.S. Food and Drug Administration (FDA), the Company is commencing its Phase 3 development program for NX-1207, Nymox's investigational product for the treatment of benign prostatic hyperplasia (BPH). The Company will begin Phase 3 clinical trials in the U.S. later this year to support a New Drug Application (NDA) to the FDA. Further information about the Phase 3 program will be provided prior to the initiation of the clinical trials.

"NX-1207 has generated excitement among leading national investigators in the trials, and Phase 3 trials have been awaited with great interest. NX-1207 is a new molecular entity with solid long-term patent protection and superior efficacy results and side effect profile to date," said Paul Averbach, Nymox's CEO. "Marketing studies have indicated this drug has the potential to radically improve BPH management and quickly become a market leader."

"We are committed to a development program for NX-1207 that will maximize shareholder benefit," he said.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

###